Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company SomaLogic Inc.
DescriptionPegylated slow off-rate modified aptamer (SOMAmer) that inhibits IL-6
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionInterleukin-6 (IL-6) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerOtsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today